Drug intelligence / Profile preview

EMP 102-Dx

Development stage: Preclinical
Lead developer: Empiriko
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EMP 102-Dx is a PSMA-targeted diagnostic imaging agent developed by Empiriko for the detection and monitoring of prostate cancer. The agent consists of a tumor-specific antibody conjugated to the positron-emitting radiometal gallium-68 (Ga-68) via a proprietary RCV (Reactive Catalytic Virus-like) carrier. By targeting the prostate-specific membrane antigen (PSMA), which is highly expressed on the surface of prostate cancer cells, EMP 102-Dx enables high-resolution positron emission tomography (PET) imaging to identify primary tumors and metastatic lesions.

Other names: Empiriko-PSMA-diagnostic radiotracerRCV + 68Ga radiotracer

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on EMP 102-Dx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP 102-Dx.

Explore the full profile